IMCRImmunocore Holdings plc
$29.39-9.8% 1Y
$29.39
$27.7952 weeks$40.22
The financials
Immunocore Holdings plc by the numbers
Immunocore Holdings plc (IMCR) reported revenue of $116M in Q2 2026 (quarter ended Jun 30, 2026), up 18% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $808K. For the full year FY2025, revenue was $400M (+29% year on year) and net income −$36M. Its largest product in Q2 2024 (quarter ended Jun 30, 2024) was Sale Of Therapies at $75M, 100% of the disclosed total, well ahead of Collaboration at 0.1%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $116M | $98M | +18% |
| Gross profit | $115M | $97M | +18% |
| Operating income | −$3.0M | −$15M | n/a |
| Net income | −$808K | −$10M | n/a |
| Diluted EPS | −$0.02 | −$0.20 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Sale Of Therapies | $75M | 100% |
| Collaboration | $53K | 0.1% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $115.9M (+8.7%)
Sale Of Therapies grew +18% year on year
Segment Latestquarter on quarteryear on year
- Sale Of Therapies$115.9M$115.9Mquarter on quarter +8.7%year on year +18%+8.7%+18%